Ionis announces GSK has advanced bepirovirsen into Phase 3 development

Initiation of the Phase 3 program expands Ionis' late-stage pipeline to 7 medicines in 9 indications CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection (CHB).

The release as fetched from its publisher. ionis.com ↗